NeuroSearch A/S expects that its suspended Phase II trial of NS2389 (GW650250A) to treat depression, will be back on track within six months after further preclinical toxicology studies.

NeuroSearch (CSE:NEUS, Ballerup, Denmark) and partner Glaxo Wellcome plc (LSE:GLXO; GLX, London, U.K.) last week announced they had suspended the trial after finding side effects in animal toxicology studies